Gaining regulatory approval for drugs targeting conditions that cannot ethically be studied in humans presents a unique challenge for drug developers. Without traditional clinical trial pathways, ...

For decades, researchers have pointed to “blue zones” as rare places where people often reach very old age in good health.

Pakistan might be witnessing its own Gen Z uprising, not through protests and violence, but in ideas that refused to be ...

Risk-free rates are much lower than in 2000, supporting higher equity valuations without replicating past bubble dynamics.

The dramatic US intervention in Venezuela has raised expectations of a rapid supply boost, but we anticipate a slower, more ...

The Geneva-Lyon leg will cover just 53 nautical miles (98 km) each way. It will, unsurprisingly, become Europe's new shortest ...

Better devices and changes in implant depth have likely led to fewer LBBBs over time, but the issue needs continued attention ...